Alpha DNA Investment Management’s Blueprint Medicines BPMC Stock Holding History

Alpha DNA Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,098	Closed	-$445K	–	33
2024 Q4	$445K	Buy	+5,098	New	+$467K	0.17%	136
2024 Q3	–	Sell	-3,879	Closed	-$418K	–	208
2024 Q2	$418K	Buy	+3,879	New	+$388K	0.16%	149
2022 Q1	–	Sell	-14,459	Closed	-$1.55M	–	123
2021 Q4	$1.55M	Buy	+14,459	New	+$1.51M	0.98%	56
2021 Q2	–	Sell	-52	Closed	-$5K	–	168
2021 Q1	$5K	Sell	52 -41	-44%	-$4.09K	0.01%	352
2020 Q4	$10K	Buy	+93	New	+$9.8K	0.01%	298

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Alpha DNA Investment Management's BPMC Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 5,098 shares — an estimated $445K sold.

Alpha DNA Investment Management first reported a position in BPMC in Q4 2020 and held it in 5 quarters. The position peaked at $1.55M in Q4 2021. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

Alpha DNA Investment Management reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
Alpha DNA Investment Management sold 5,098 Blueprint Medicines shares in Q1 2025, an estimated $445K.
Alpha DNA Investment Management first reported a position in Blueprint Medicines in Q4 2020 and held it in 5 quarters.
Alpha DNA Investment Management's Blueprint Medicines position peaked at $1.55M in Q4 2021.
352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.